# Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)

> **NCT04394624** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 31 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** SAR408701
- **DRUG:** ramucirumab
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT04394624
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-31
- **Primary completion:** 2023-03-06
- **Final completion:** 2024-10-24
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Sponsor decision, the decision is not related to any safety concern.
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04394624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04394624, "Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04394624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*